Compile Data Set for Download or QSAR
maximum 50k data
Found 1547 with Last Name = 'fieldhouse' and Initial = 'c'
TargetProstaglandin E2 receptor EP1 subtype(Homo sapiens (Human))
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50419411(CHEMBL1915012)
Affinity DataKi:  0.398nMAssay Description:Antagonist activity at human recombinant EP1 receptor expressed in CHO-K1 cells assessed as inhibition of PGE2-mediated intracellular calcium mobiliz...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetProstaglandin E2 receptor EP3 subtype(Homo sapiens (Human))
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50419411(CHEMBL1915012)
Affinity DataKi:  1.00E+3nMAssay Description:Antagonist activity at human recombinant EP3 receptor expressed in CHO-K1 cells assessed as inhibition of PGE2-mediated intracellular calcium mobiliz...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256877(US9493432, 1)
Affinity DataIC50:  0.840nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256953(US9493432, 79)
Affinity DataIC50:  1nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256957(US9493432, 83)
Affinity DataIC50:  1nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256955(US9493432, 81)
Affinity DataIC50:  1nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256954(US9493432, 80)
Affinity DataIC50:  1nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProstaglandin E2 receptor EP1 subtype(Homo sapiens (Human))
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50419410(CHEMBL1915252)
Affinity DataIC50:  2nMAssay Description:Displacement of [3H]GW875240X from human prostanoid EP1 receptor expressed in CHO-K1 cells after 45 mins by topcount liquid scintillation countingMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetD-amino-acid oxidase(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM210775(US10463663, Example 4 | US11129828, Example 4 | US...)
Affinity DataIC50:  3.70nMAssay Description:The functional activity of compounds inhibiting the DAAO enzyme was determined by utilizing the co-product of the catalysis of D-Serine, H2O2 which c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetD-amino-acid oxidase(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM210775(US10463663, Example 4 | US11129828, Example 4 | US...)
Affinity DataIC50:  3.70nMpH: 7.4 T: 2°CAssay Description:Human DAAO enzyme was supplied by the Takeda Pharmaceutical Company (Osaka) and each batch was tested and used at concentrations giving comparable le...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetD-amino-acid oxidase(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM210775(US10463663, Example 4 | US11129828, Example 4 | US...)
Affinity DataIC50:  3.70nMAssay Description:Human DAAO enzyme was supplied by the Takeda Pharmaceutical Company (Osaka) and each batch was tested and used at concentrations giving comparable le...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetD-amino-acid oxidase(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM210775(US10463663, Example 4 | US11129828, Example 4 | US...)
Affinity DataIC50:  3.70nMAssay Description:Human DAAO enzyme was supplied by the Takeda Pharmaceutical Company (Osaka) and each batch was tested and used at concentrations giving comparable le...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProstaglandin E2 receptor EP1 subtype(Homo sapiens (Human))
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50419415(CHEMBL1915015)
Affinity DataIC50:  3.98nMAssay Description:Displacement of [3H]GW875240X from human prostanoid EP1 receptor expressed in CHO-K1 cells after 45 mins by topcount liquid scintillation countingMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256879(US9493432, 3)
Affinity DataIC50:  4.20nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256910(US9493432, 34)
Affinity DataIC50:  4.70nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185336(US10011588, Example 158 | US10689373, Example 158 ...)
Affinity DataIC50:  5nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256949(US9493432, 75)
Affinity DataIC50:  5nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185336(US10011588, Example 158 | US10689373, Example 158 ...)
Affinity DataIC50:  5nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca.sup.2+ sensitive fluorescent dye. The chang...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185336(US10011588, Example 158 | US10689373, Example 158 ...)
Affinity DataIC50:  5nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProstaglandin E2 receptor EP1 subtype(Homo sapiens (Human))
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50419411(CHEMBL1915012)
Affinity DataIC50:  5.01nMAssay Description:Displacement of [3H]PGE2 from human prostanoid EP1 receptor expressed in CHO-K1 cells after 30 mins by topcount liquid scintillation countingMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetProstaglandin E2 receptor EP1 subtype(Homo sapiens (Human))
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50419403(CHEMBL1914467)
Affinity DataIC50:  5.01nMAssay Description:Displacement of [3H]GW875240X from human prostanoid EP1 receptor expressed in CHO-K1 cells after 45 mins by topcount liquid scintillation countingMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetProstaglandin E2 receptor EP1 subtype(Homo sapiens (Human))
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50419417(CHEMBL1915254)
Affinity DataIC50:  5.01nMAssay Description:Displacement of [3H]GW875240X from human prostanoid EP1 receptor expressed in CHO-K1 cells after 45 mins by topcount liquid scintillation countingMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetD-amino-acid oxidase(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM210789(US10463663, Example 24 | US11129828, Example 24 | ...)
Affinity DataIC50:  6nMAssay Description:The functional activity of compounds inhibiting the DAAO enzyme was determined by utilizing the co-product of the catalysis of D-Serine, H2O2 which c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetD-amino-acid oxidase(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM210789(US10463663, Example 24 | US11129828, Example 24 | ...)
Affinity DataIC50:  6nMpH: 7.4 T: 2°CAssay Description:Human DAAO enzyme was supplied by the Takeda Pharmaceutical Company (Osaka) and each batch was tested and used at concentrations giving comparable le...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185275(US10011588, Example 91 | US10689373, Example 91 | ...)
Affinity DataIC50:  6nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca.sup.2+ sensitive fluorescent dye. The chang...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetD-amino-acid oxidase(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM210789(US10463663, Example 24 | US11129828, Example 24 | ...)
Affinity DataIC50:  6nMAssay Description:Human DAAO enzyme was supplied by the Takeda Pharmaceutical Company (Osaka) and each batch was tested and used at concentrations giving comparable le...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185275(US10011588, Example 91 | US10689373, Example 91 | ...)
Affinity DataIC50:  6nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetD-amino-acid oxidase(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM210789(US10463663, Example 24 | US11129828, Example 24 | ...)
Affinity DataIC50:  6nMAssay Description:Human DAAO enzyme was supplied by the Takeda Pharmaceutical Company (Osaka) and each batch was tested and used at concentrations giving comparable le...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185275(US10011588, Example 91 | US10689373, Example 91 | ...)
Affinity DataIC50:  6nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProstaglandin E2 receptor EP1 subtype(Homo sapiens (Human))
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50419419(CHEMBL1915262)
Affinity DataIC50:  6.31nMAssay Description:Displacement of [3H]GW875240X from human prostanoid EP1 receptor expressed in CHO-K1 cells after 45 mins by topcount liquid scintillation countingMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256911(US9493432, 35)
Affinity DataIC50:  6.70nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185265(US10011588, Example 81 | US10689373, Example 81 | ...)
Affinity DataIC50:  7nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca.sup.2+ sensitive fluorescent dye. The chang...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185325(US10011588, Example 146 | US10689373, Example 146 ...)
Affinity DataIC50:  7nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca.sup.2+ sensitive fluorescent dye. The chang...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256979(US9493432, 107)
Affinity DataIC50:  7nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185325(US10011588, Example 146 | US10689373, Example 146 ...)
Affinity DataIC50:  7nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185265(US10011588, Example 81 | US10689373, Example 81 | ...)
Affinity DataIC50:  7nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185325(US10011588, Example 146 | US10689373, Example 146 ...)
Affinity DataIC50:  7nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185265(US10011588, Example 81 | US10689373, Example 81 | ...)
Affinity DataIC50:  7nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProstaglandin E2 receptor EP1 subtype(Homo sapiens (Human))
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50419408(CHEMBL1915261)
Affinity DataIC50:  7.94nMAssay Description:Displacement of [3H]GW875240X from human prostanoid EP1 receptor expressed in CHO-K1 cells after 45 mins by topcount liquid scintillation countingMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185271(US10011588, Example 87 | US10689373, Example 87 | ...)
Affinity DataIC50:  8nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185287(US10011588, Example 103 | US10689373, Example 103 ...)
Affinity DataIC50:  8nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185276(US10011588, Example 92 | US10689373, Example 92 | ...)
Affinity DataIC50:  8nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185271(US10011588, Example 87 | US10689373, Example 87 | ...)
Affinity DataIC50:  8nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185332(US10011588, Example 155 | US10689373, Example 155 ...)
Affinity DataIC50:  8nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185287(US10011588, Example 103 | US10689373, Example 103 ...)
Affinity DataIC50:  8nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185271(US10011588, Example 87 | US10689373, Example 87 | ...)
Affinity DataIC50:  8nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca.sup.2+ sensitive fluorescent dye. The chang...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185276(US10011588, Example 92 | US10689373, Example 92 | ...)
Affinity DataIC50:  8nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca.sup.2+ sensitive fluorescent dye. The chang...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185287(US10011588, Example 103 | US10689373, Example 103 ...)
Affinity DataIC50:  8nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca.sup.2+ sensitive fluorescent dye. The chang...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185332(US10011588, Example 155 | US10689373, Example 155 ...)
Affinity DataIC50:  8nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca.sup.2+ sensitive fluorescent dye. The chang...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185276(US10011588, Example 92 | US10689373, Example 92 | ...)
Affinity DataIC50:  8nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
Displayed 1 to 50 (of 1547 total ) | Next | Last >>
Jump to: